Asit, this week, competitor Novo Nordisk out with earnings and news that their blockbuster weight drug, Wegovy posted better ...

SINGAPORE - Media OutReach Newswire - 22 December 2023 - Novo Nordisk Pharma (Thailand) Ltd. has emerged triumphant by securing three prestigious accolades at the Asia Pacific Enterprise Awards (APEA) ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk's (NVO) third-quarter earnings were solid enough to soothe investor jitters and turn the market's attention toward upcoming trial results for a potentially game-changing new weight-loss ...

The ‘Ozempic drug,’ semaglutide, has been found to reduce moderately severe pain caused by knee osteoarthritis and improve ...

Drugmaker Lupin aims to be part of the first wave of generic drugmakers to make GLP-1 receptor agonists products, used to ...

A Novo Nordisk trial also discovered an association between Wegovy prescriptions and fewer hospitalizations for any cause. In the study, 33.4% of patients taking Wegovy were admitted, compared to ...

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

The FDA, however, warns that reports in a database aren’t yet verified and don’t mean the drugs have actually caused the harms reported.

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...